Testing for rare genetic mutation not standard of care – Defense Verdict 

Patient died fol­lowing one cycle of FOLFOX che­motherapy after a diagnosis of Stage IIIB colon cancer. It was later deter­mined that patient had a rare genetic mutation that af­fected his ability to metabolize 5-FU, the active agent in FOLFOX. Adminis­trator alleged that medical oncologist failed to proper­ly obtain patient’s informed consent because medical oncologist did ...